A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults

ABSTRACT TransCon PTH is a sustained‐release, essentially inactive prodrug transiently bound to an inert carrier, designed to release PTH(1‐34), and in development for hypoparathyroidism (HP). This phase 1, randomized, placebo‐controlled, single and multiple ascending dose (SAD and MAD, respectively...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral research 2020-08, Vol.35 (8), p.1430-1440
Hauptverfasser:	Karpf, David B, Pihl, Susanne, Mourya, Sanchita, Mortensen, Eva, Kovoor, Eshwari, Markova, Denka, Leff, Jonathan A
Format:	Artikel
Sprache:	eng
Schlagworte:	Albumin Alkaline phosphatase Bone growth Bone resorption Bone turnover Calcium Calcium (blood) CLINICAL TRIALS Collagen DISORDERS OF CALCIUM/PHOSPHATE METABOLISM Double-blind studies Glomerular filtration rate Hypercalcemia HYPOPARATHYROIDISM LONG ACTING PTH Magnesium Original Osteoblasts Osteoclasts Osteogenesis Parathyroid hormone Pharmacodynamics Pharmacokinetics Phosphates PTH Reabsorption THERAPEUTICS Vitamin D
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!